Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 9/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 18/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278306 | 0.84 | NR3C2 (0.49) | NR3C2NR3C1KDM4E | |
| Hydrochloric Acid SCHEMBL31410008 | 0.83 | NR3C2 (0.40) | NR3C2NR3C1KDM4E | |
| SCHEMBL14488872 | 0.81 | NR3C2 (0.47) | NR3C2NR3C1KDM4EPGR | |
| SCHEMBL4309317 | 0.81 | NR3C2 (0.54) | NR3C2NR3C1PGR | |
| SCHEMBL13347573 | 0.80 | NR3C2 (0.49) | NR3C2NR3C1PGR | |
| SCHEMBL23417033 | 0.78 | NR3C2 (0.44) | NR3C2NR3C1PGR | |
| SCHEMBL5295501 | 0.78 | CA12 (0.54) | — | |
| SCHEMBL27536429 | 0.78 | ALDH1A1 (0.47) | KDM4E | |
| SCHEMBL31658735 | 0.77 | NR3C1 (0.49) | NR3C1 | |
| SCHEMBL5915652 | 0.77 | GAA (0.44) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326257-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220348568-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | INC., CHEMOCENTRYX | 2022-11-03 | — | — | US | disclosed |
| WO-2022225832-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| WO-2015037716-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 住友化学株式会社 (JP) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348568-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | CXCR1, CXCR5, CXCR6 | NR3C2 287/4885NR3C1 845/4885KDM4E 3817/4885 |
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, HRH4 | NR3C2 42/4885NR3C1 196/4885KDM4E 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.